Edema News and Research

RSS
Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.
Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

Blocking IL-1 signalling molecule could alleviate asthma symptoms

Blocking IL-1 signalling molecule could alleviate asthma symptoms

Scientists develop new drug for life-threatening lung disease treatment

Scientists develop new drug for life-threatening lung disease treatment

Professor outlines effects of sports-specific counseling on injury outcomes in youth athletes

Professor outlines effects of sports-specific counseling on injury outcomes in youth athletes

Inserm study reveals potential of secondary system to improve heart function

Inserm study reveals potential of secondary system to improve heart function

Bariatric surgery improves pain, physical function in obese patients

Bariatric surgery improves pain, physical function in obese patients

Edema Guard Monitor appears to reduce heart failure-related hospitalizations by more than half

Edema Guard Monitor appears to reduce heart failure-related hospitalizations by more than half

Inhalable form of Ambrisentan drug could offer faster-acting treatment option for pulmonary edema

Inhalable form of Ambrisentan drug could offer faster-acting treatment option for pulmonary edema

Novel mechanism can suppress blood vessel leakage, reduce tumour spread in mice

Novel mechanism can suppress blood vessel leakage, reduce tumour spread in mice

Innovative treatment may help prevent brain swelling, death in stroke patients

Innovative treatment may help prevent brain swelling, death in stroke patients

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

World Kidney Day 2016 focuses on children

World Kidney Day 2016 focuses on children

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Lilly receives FDA approval for Humulin R U-500 KwikPen

Lilly receives FDA approval for Humulin R U-500 KwikPen

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.